Pages that link to "Q30619387"
Jump to navigation
Jump to search
The following pages link to A model-based approach to predict longitudinal HbA1c, using early phase glucose data from type 2 diabetes mellitus patients after anti-diabetic treatment. (Q30619387):
Displaying 10 items.
- Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes (Q38558336) (← links)
- A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development (Q38707493) (← links)
- Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment (Q38838596) (← links)
- Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart. (Q46132737) (← links)
- Model-Based Interspecies Scaling of Glucose Homeostasis (Q46299047) (← links)
- Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study. (Q50223164) (← links)
- Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. (Q51304445) (← links)
- Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes. (Q55176938) (← links)
- Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus (Q64816409) (← links)
- Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests (Q88586137) (← links)